Viruses
(Jun 2021)
Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil
Cassia F. Estofolete,
Cecilia A. Banho,
Guilherme R. F. Campos,
Beatriz de C. Marques,
Livia Sacchetto,
Leila S. Ullmann,
Fabio S. Possebon,
Luana F. Machado,
Juliana D. Syrio,
João P. Araújo Junior,
Cintia Bittar,
Paula Rahal,
Suzana M. A. Lobo,
Helena Lage Ferreira,
Nikos Vasilakis,
Mauricio L. Nogueira
Affiliations
Cassia F. Estofolete
Laboratório de Pesquisas em Virologia (LPV), Medicine School of São José do Rio Preto (FAMERP), São José do Rio Preto, São Paulo 15090-000, Brazil
Cecilia A. Banho
Laboratório de Pesquisas em Virologia (LPV), Medicine School of São José do Rio Preto (FAMERP), São José do Rio Preto, São Paulo 15090-000, Brazil
Guilherme R. F. Campos
Laboratório de Pesquisas em Virologia (LPV), Medicine School of São José do Rio Preto (FAMERP), São José do Rio Preto, São Paulo 15090-000, Brazil
Beatriz de C. Marques
Laboratório de Pesquisas em Virologia (LPV), Medicine School of São José do Rio Preto (FAMERP), São José do Rio Preto, São Paulo 15090-000, Brazil
Livia Sacchetto
Laboratório de Pesquisas em Virologia (LPV), Medicine School of São José do Rio Preto (FAMERP), São José do Rio Preto, São Paulo 15090-000, Brazil
Leila S. Ullmann
Biotecnology Institute, São Paulo State University (UNESP), Botucatu, São Paulo 18607-440, Brazil
Fabio S. Possebon
Biotecnology Institute, São Paulo State University (UNESP), Botucatu, São Paulo 18607-440, Brazil
Luana F. Machado
Hospital de Base, São José do Rio Preto, São Paulo 15090-000, Brazil
Juliana D. Syrio
Hospital de Base, São José do Rio Preto, São Paulo 15090-000, Brazil
João P. Araújo Junior
Biotecnology Institute, São Paulo State University (UNESP), Botucatu, São Paulo 18607-440, Brazil
Cintia Bittar
Intitute of Biosciences, Languages and Exact Sciences, São Paulo State University (UNESP), São José do Rio Preto, São Paulo 15054-000, Brazil
Paula Rahal
Intitute of Biosciences, Languages and Exact Sciences, São Paulo State University (UNESP), São José do Rio Preto, São Paulo 15054-000, Brazil
Suzana M. A. Lobo
Hospital de Base, São José do Rio Preto, São Paulo 15090-000, Brazil
Helena Lage Ferreira
Department of Veterinary Medicine FZEA-USP, University of São Paulo (USP), Pirassununga, São Paulo 13635-900, Brazil
Nikos Vasilakis
Department of Pathology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555, USA
Mauricio L. Nogueira
Laboratório de Pesquisas em Virologia (LPV), Medicine School of São José do Rio Preto (FAMERP), São José do Rio Preto, São Paulo 15090-000, Brazil
DOI
https://doi.org/10.3390/v13071237
Journal volume & issue
Vol. 13,
no. 7
Abstract
Read online
The rapid development of efficacious and safe vaccines against coronavirus disease 2019 (COVID-19) has been instrumental in mitigating the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Moreover, the emergence of SARS-CoV-2 variants raised concerns on the efficacy of these vaccines. Herein, we report two cases of breakthrough infections with the P1 variant in patients vaccinated with CoronaVac, which is one of the two vaccines authorized for emergency use in the Brazilian immunization program. Our observations suggest that the vaccine reduced the severity of the disease and highlight the potential risk of illness following vaccination and subsequent infection with the P1 variant as well as for continued efforts to prevent and diagnose infection in vaccinated persons.
Keywords
WeChat QR code
Close
